UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
August 8, 2005
----------------
Date of Report (Date of earliest event reported)
OSI PHARMACEUTICALS, INC.
-------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-15190 13-3159796
---------- ---------- -----------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
58 South Service Road
Melville, NY 11747
----------------------------------------
(Address of principal executive offices)
(631) 962-2000
-------------------------
(Registrant's telephone number, including area code)
N/A
---------------
(Former name or former address,
if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a- 12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 Other Events
On August 8, 2005, OSI Pharmaceuticals, Inc. ("OSI") issued a press release
announcing that the Oncologic Drugs Advisory Committee panel will review at its
September 13, 2005 meeting the use of Tarceva(R) (erlotinib) plus gemcitabine
chemotherapy for the treatment of advanced pancreatic cancer in patients who
have not received any previous treatment. Details regarding the review are set
forth in OSI's press release dated August 8, 2005 which is attached hereto as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference.
ITEM 9.01 EXHIBITS
EXHIBIT NO. DESCRIPTION
- ----------- -----------
99.1 Press release, dated August 8, 2005.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 19, 2005 OSI PHARMACEUTICALS, INC.
----------------
By: /s/ MICHAEL G. ATIEH
----------------------
Michael G. Atieh
Executive Vice President and
Chief Financial Officer
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
- ----------- -----------
99.1 Press release, dated August 8, 2005.